Showing 1 to 12 of 23 results
Moderna Defends UK Drug Pricing Amid Industry Criticism
Moderna opened a \£150 million vaccine facility in Oxfordshire, defending the UK's drug pricing system after criticism from other pharmaceutical companies who have paused investments due to pricing disputes with the government.
Moderna Defends UK Drug Pricing Amid Industry Criticism
Moderna opened a \£150 million vaccine facility in Oxfordshire, defending the UK's drug pricing system after criticism from other pharmaceutical companies who have paused investments due to pricing disputes with the government.
Progress
32% Bias Score
Pfizer Publishes Covid-19 Vaccine Data Following Trump's Call for Transparency
Responding to President Trump's request, Pfizer released over 200 news releases, 27 peer-reviewed publications, and pledged more data on its Covid-19 vaccine's impact, highlighting its role in saving millions of lives and boosting the economy.
Pfizer Publishes Covid-19 Vaccine Data Following Trump's Call for Transparency
Responding to President Trump's request, Pfizer released over 200 news releases, 27 peer-reviewed publications, and pledged more data on its Covid-19 vaccine's impact, highlighting its role in saving millions of lives and boosting the economy.
Progress
36% Bias Score
FDA May Not Renew Pfizer's Covid-19 Vaccine for Young Children, Creating Potential Shortage
The US Food and Drug Administration (FDA) may not renew Pfizer's Covid-19 vaccine for children under five this fall, creating a potential vaccine shortage as Moderna's vaccine is only approved for children with pre-existing health conditions; this impacts the already low vaccination rates among this...
FDA May Not Renew Pfizer's Covid-19 Vaccine for Young Children, Creating Potential Shortage
The US Food and Drug Administration (FDA) may not renew Pfizer's Covid-19 vaccine for children under five this fall, creating a potential vaccine shortage as Moderna's vaccine is only approved for children with pre-existing health conditions; this impacts the already low vaccination rates among this...
Progress
40% Bias Score
US Cuts Funding for Moderna Bird Flu Vaccine Amidst Controversy
The Trump administration cut a $766 million grant for Moderna's experimental bird flu vaccine, citing unmet scientific standards; however, Pfizer's CEO defended the vaccine's efficacy, highlighting the success of mRNA vaccines and expressing concern about declining vaccination rates.
US Cuts Funding for Moderna Bird Flu Vaccine Amidst Controversy
The Trump administration cut a $766 million grant for Moderna's experimental bird flu vaccine, citing unmet scientific standards; however, Pfizer's CEO defended the vaccine's efficacy, highlighting the success of mRNA vaccines and expressing concern about declining vaccination rates.
Progress
64% Bias Score
Trump Administration Terminates $750 Million in Funding for Moderna's mRNA Bird Flu Vaccine
The Trump administration terminated over $750 million in funding for Moderna's mRNA bird flu vaccine development, citing safety and ethical concerns, following previous funding from the Biden administration totaling $766 million; this reflects a broader policy shift prioritizing older populations an...
Trump Administration Terminates $750 Million in Funding for Moderna's mRNA Bird Flu Vaccine
The Trump administration terminated over $750 million in funding for Moderna's mRNA bird flu vaccine development, citing safety and ethical concerns, following previous funding from the Biden administration totaling $766 million; this reflects a broader policy shift prioritizing older populations an...
Progress
64% Bias Score
HHS Terminates Moderna Bird Flu Vaccine Contract
The US Department of Health and Human Services terminated a $590 million contract with Moderna to develop an mRNA-based bird flu vaccine due to safety and ethical concerns, despite Moderna's positive trial results, leaving the future of the project uncertain and raising concerns about pandemic prepa...
HHS Terminates Moderna Bird Flu Vaccine Contract
The US Department of Health and Human Services terminated a $590 million contract with Moderna to develop an mRNA-based bird flu vaccine due to safety and ethical concerns, despite Moderna's positive trial results, leaving the future of the project uncertain and raising concerns about pandemic prepa...
Progress
56% Bias Score
UK Medicine Prices Must Rise to Attract Pharmaceutical Investment, Says Science Minister
Science minister Patrick Vallance says the UK must raise NHS medicine prices to prevent pharmaceutical companies from pulling investment from the country, following recent project cancellations by major drugmakers.
UK Medicine Prices Must Rise to Attract Pharmaceutical Investment, Says Science Minister
Science minister Patrick Vallance says the UK must raise NHS medicine prices to prevent pharmaceutical companies from pulling investment from the country, following recent project cancellations by major drugmakers.
Progress
48% Bias Score
Moderna Merges HR and IT to Create AI-First Company
Moderna, a biotech giant, merged its human resources and information technology departments under one leader, Tracey Franklin, to build an agile, AI-first company, deploying over 3,000 GPT-based agents to automate tasks and enhance efficiency, while acknowledging potential cultural and operational c...
Moderna Merges HR and IT to Create AI-First Company
Moderna, a biotech giant, merged its human resources and information technology departments under one leader, Tracey Franklin, to build an agile, AI-first company, deploying over 3,000 GPT-based agents to automate tasks and enhance efficiency, while acknowledging potential cultural and operational c...
Progress
40% Bias Score
Moderna Stock Plummets 80% on Reduced COVID-19 Vaccine Sales
Moderna's stock price has fallen over 80% in the last year due to an 83% decrease in revenue from its COVID-19 vaccine, dropping from $18.9 billion in 2022 to $3.1 billion over the last twelve months, and projected to reach $2.1 billion in 2025; this is primarily because of reduced demand as the pan...
Moderna Stock Plummets 80% on Reduced COVID-19 Vaccine Sales
Moderna's stock price has fallen over 80% in the last year due to an 83% decrease in revenue from its COVID-19 vaccine, dropping from $18.9 billion in 2022 to $3.1 billion over the last twelve months, and projected to reach $2.1 billion in 2025; this is primarily because of reduced demand as the pan...
Progress
56% Bias Score
Trump Administration Cancels $766 Million Moderna Flu Vaccine Contract
The Trump administration cancelled two Moderna contracts worth $766 million for H5N1 bird flu vaccines following positive trial results, citing insufficient testing of mRNA technology, despite a prior US bird flu outbreak resulting in one death.
Trump Administration Cancels $766 Million Moderna Flu Vaccine Contract
The Trump administration cancelled two Moderna contracts worth $766 million for H5N1 bird flu vaccines following positive trial results, citing insufficient testing of mRNA technology, despite a prior US bird flu outbreak resulting in one death.
Progress
44% Bias Score
U.S. Cancels $766M Bird Flu Vaccine Contract, Raising Pandemic Preparedness Concerns
The U.S. government cancelled a $766 million contract with Moderna for an mRNA H5N1 bird flu vaccine due to safety concerns, prompting criticism from experts who warn of reduced pandemic preparedness.
U.S. Cancels $766M Bird Flu Vaccine Contract, Raising Pandemic Preparedness Concerns
The U.S. government cancelled a $766 million contract with Moderna for an mRNA H5N1 bird flu vaccine due to safety concerns, prompting criticism from experts who warn of reduced pandemic preparedness.
Progress
60% Bias Score
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
Progress
40% Bias Score
Showing 1 to 12 of 23 results